Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Barclays PLC

Barclays PLC lowered its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 69.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 370,894 shares of the company’s stock after selling 846,137 shares during the period. Barclays PLC’s holdings in Guardant Health were worth $11,333,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Guardant Health in the fourth quarter worth about $26,000. SBI Securities Co. Ltd. purchased a new stake in shares of Guardant Health during the 4th quarter worth about $43,000. Kimelman & Baird LLC acquired a new stake in shares of Guardant Health during the 4th quarter valued at about $58,000. Quantbot Technologies LP bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $80,000. Finally, Jones Financial Companies Lllp lifted its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after acquiring an additional 817 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on GH. Guggenheim reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. Stifel Nicolaus boosted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Barclays cut their price objective on Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group lifted their price target on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Twenty analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $49.00.

Guardant Health Stock Performance

Shares of GH opened at $42.61 on Tuesday. The business’s fifty day moving average price is $43.50 and its two-hundred day moving average price is $36.71. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -11.97 and a beta of 1.45. Guardant Health, Inc. has a 52 week low of $16.77 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.